Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 19.6% and free cash flow fell 43.0%, each against the same quarter a year earlier.

71.93 1.94 −2.63%
Market cap
$4.9B
P/E
0.0×
Fwd P/E
—
Dividend yield
0.00%
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

16.94 22.37 23.76 38.51
Net Debt/EBITDA
9.94 9.61 10.56 17.12
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.49) (0.50) (0.43) (0.53)
Book value per Share
11.05 10.35 8.82 17.73
Free Cash Flow
(21.70) (22.66) (23.65) (33.14)
Other line items

Show all line items

Columns are period end dates